002007 Hualan Biological Engineering, Inc.
- 16.40
- +0.07+0.43%
Hualan Biological Engineering, Inc. News
Hualan Biological Engineering, Inc. (002007.SZ): As of July 10th, the company has more than 1.5 million investors.
As of July 10, 2024, hualan biological engineering, inc. had over 1.5 million investors on its investor interaction platform.
GLE Announcements Selection: Zhuhai Guanyu Plans to Invest Not More Than 2 Billion Yuan in Malaysia Guanyu New Energy Project; Zijin Mining Group: Net Income Is Expected to Increase by About 41%-50% YoY in the First Half of the Year.
Investment project: Zhuhai Guanyu (688772.SH): plans to invest no more than 2 billion yuan to build new energy projects for Guanyu batteries in Malaysia; Tianyuan Group (002386.SZ): Haifeng and Rui plan to invest 0.136 billion yuan to build an optimized ion membrane electrolysis tank project for chlor-alkali plant; Tianyuan Group (002386.SZ): Haifeng and Tai plan to invest 73.8971 million yuan in the quality improvement optimization technology transformation project for titanium dioxide; Tianyuan Group (002386.SZ): Haifeng and Rui plan to invest 72.61 million yuan to build a 40MW/80WWh user-side electrochemical energy storage power station.
Express News | Hualan Biological Says Chairman, Senior Execs Plan to Increase Holdings in the Company by 1.2-2.4 Mln Shares Within Six Months
Hualan Biological Engineering Inc. (SZSE:002007) Stock Goes Ex-Dividend In Just Three Days
Regular readers will know that we love our dividends at Simply Wall St, which is why it's exciting to see Hualan Biological Engineering Inc. (SZSE:002007) is about to trade ex-dividend in the next 3 d
Shareholders in Hualan Biological Engineering (SZSE:002007) Are in the Red If They Invested Three Years Ago
Investing in stocks inevitably means buying into some companies that perform poorly. Long term Hualan Biological Engineering Inc. (SZSE:002007) shareholders know that all too well, since the share pr
Huaxin Securities: Both the supply and demand sides of blood products continue to improve, and the scale effect of leading companies gradually emerges.
According to the research reports released by Huaxin Securities, with the support and attention of domestic policies, the planning of new plasma stations such as the "14th Five-Year Plan" will gradually be implemented, and the construction of plasma stations will accelerate. China's plasma collection scale will continue to increase. In 2023, the plasma collection volume will exceed 12079 tons, an increase of more than 18.6% compared with 2022. Blood products belong to essential pharmaceuticals, and the entire industry is a licensed business, which determines its natural high policy barrier characteristics. The scale of plasma collection, the comprehensive utilization rate of blood plasma, and the profit-making ability of blood plasma are the core factors. The scale of plasma collection directly determines the scale of the enterprise. The number of existing varieties and research products are used to determine the comprehensive utilization rate and profit-making ability of blood plasma.
Hualan Biological Reduce Quadrivalent Influenza Vaccine Prices
Hualan Biological (SHE:002007) adjusted the prices of quadrivalent influenza vaccine products starting from June 5, according to a Wednesday filing on the Shenzhen bourse. The company expects a negati
Hualan Biological Engineering, Inc. (002007.SZ): 10 shares and 3 yuan per share for equity distribution in 2023, with a registration date of June 13th.
On June 5, Gelunhui reported that Hualan Biological Engineering, Inc. (002007.SZ) announced its annual equity distribution plan for 2023: based on the company's existing total share capital of 1,828,780,926 shares, it will distribute RMB 3 in cash (tax included) for every 10 shares to all shareholders. The equity distribution record date for this distribution is June 13, 2024, and the ex-rights and ex-dividend date is June 14, 2024.
Express News | Hualan Biological Says Unit Reduces Prices of Flu Vaccine Products and May Affect Co's Revenue
Hualan Biological Engineering, Inc. (002007.SZ): Its subsidiary adjusts the price of quadrivalent influenza vaccine products.
On June 5th, Gelonhui reported that hualan biological engineering, inc. (002007.SZ) decided to adjust the prices of its quadrivalent influenza vaccine products from June 5, 2024 in order to improve the accessibility of influenza vaccines, enhance the company's product market competitiveness and market share, ease the economic burden of the people and the government, and fulfill corporate social responsibility. The adjusted quadrivalent influenza split virus vaccine (adult dosage, pre-filled 0.5ml/support) is set to 88 yuan / support, while the quadrivalent influenza virus vaccine.
Hualan Biological Engineering Inc.'s (SZSE:002007) Intrinsic Value Is Potentially 28% Above Its Share Price
Key Insights Using the 2 Stage Free Cash Flow to Equity, Hualan Biological Engineering fair value estimate is CN¥25.65 Current share price of CN¥20.07 suggests Hualan Biological Engineering is poten
Hualan Biological Engineering's Blood Centers Get License to Operate
Two of Hualan Biological Engineering's (SHE:002007) blood collecting centers are now allowed to operate after receiving licenses from the health commission of China's Henan Province, the company said
A subsidiary of Hualan Biology (002007.SZ) obtained a single plasma collection license
Zhitong Finance App News, Hualan Biology (002007.SZ) announced that on May 15, 2024, Hualan Biotech Qixian Single Plasma Collection Station and Hualan Biotech Xiangcheng Single Plasma Collection Station, which are affiliated with the company, obtained the “Single Plasma Collection License” issued by the Henan Provincial Health Commission.
Hualan Biological Engineering Inc.'s (SZSE:002007) Top Owners Are Retail Investors With 38% Stake, While 29% Is Held by Private Companies
Key Insights Significant control over Hualan Biological Engineering by retail investors implies that the general public has more power to influence management and governance-related decisions The to
Hualan Biology (002007.SZ): Intravenous human immunoglobulin (IVIG) (10%) is in phase III clinical trials
Gelonghui, April 15 | Hualan Biology (002007.SZ) said on the investor interactive platform that intravenous human immunoglobulin (IVIG) (10%) developed by the company is in phase III clinical trials.
Is Hualan Biological Engineering (SZSE:002007) A Risky Investment?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously said that 'Volatility is far from synonymous with risk.' So it seems the smart m
Hualan Biological Engineering's Profit Rises 38%; Tops EPS, Revenue Estimates
Hualan Biological Engineering's (SHE:002007) attributable profit rose 37.66% to 1.48 billion yuan in 2023 from 1.08 billion yuan in 2022, according to a Tuesday filing with the Shenzhen bourse. Earnin
Hualan Biotech (002007.SZ): Net profit for 2023 increased by 37.66% to 1,482 billion yuan, plans to pay 10 to 3 yuan
Gelonghui, March 29 | Hualan Biotech (002007.SZ) announced its 2023 annual report. In 2023, the company achieved operating income of 5.342 billion yuan, up 18.26% year on year; net profit attributable to shareholders of listed companies was 1,482 billion yuan, up 37.66% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 1,267 billion yuan, an increase of 41.77% year on year; basic income per share was 0.8121 yuan; it plans to distribute a cash dividend of 3 yuan (tax included) for every 10 shares to all shareholders.
Some Confidence Is Lacking In Hualan Biological Engineering Inc.'s (SZSE:002007) P/E
It's not a stretch to say that Hualan Biological Engineering Inc.'s (SZSE:002007) price-to-earnings (or "P/E") ratio of 28.5x right now seems quite "middle-of-the-road" compared to the market in Chin
Hualan Biology (002007.SZ): Currently, there are 32 single plasma collection stations (including sub-stations)
Gelonghui, March 13 | Hualan Biotech (002007.SZ) said on the investor interactive platform that the company currently has 32 single plasma collection stations (including sub-stations), including 4 in Guangxi, 1 in Guizhou, 15 in Chongqing, and 12 in Henan. Among them, plasma stations in Xiangcheng County and Qi County are proceeding with the construction of single plasma collection stations according to the plan, and are expected to be completed and accepted in 2024.
Analysis
Price Target
No Data
